Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
|Videos|December 20, 2019
Management of HER2 Expression in Breast Cancer
Author(s)Sponsored Content
Ian E. Krop, MD, PhD, provides insight on HER2 expression in breast cancer, treatment for blocking HER2, and the management of newly diagnosed HER2+ metastatic breast cancer with T-DM1.
Advertisement
Ian E. Krop, MD, PhD, provides insight on HER2 expression in breast cancer, treatment for blocking HER2, and the management of newly diagnosed HER2+ metastatic breast cancer with T-DM1.
Advertisement
Related to this article
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.
Dr. Doured Daghistani explains how pediatric oncology is shifting toward reducing long-term side effects as childhood cancer survival rates rise.
Cancer can change, hide from the immune system and escape treatment, making effective therapy about more than targeting cancer cells alone.
Advertisement
Advertisement
Trending on CURE
1
Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing
2
Top 3 Takeaways From WCLC 2026 That Patients Should Know
3
Imfinzi Plus Chemotherapy Raises 3-Year Survival to 69% in Gastric Cancer
4
Childhood Leukemia Survivor Shares Her Experience With ALL, Relapse and CAR-T
5